Andreas MD - Telix Pharmaceuticals Chief Advisor
| TLX Stock | 16.49 1.07 6.94% |
Executive
Andreas MD is Chief Advisor of Telix Pharmaceuticals Limited
| Age | 59 |
| Address | 55 Flemington Road, North Melbourne, VIC, Australia, 3051 |
| Phone | 61 3 9093 3855 |
| Web | https://telixpharma.com |
Telix Pharmaceuticals Management Efficiency
The company has Return on Asset of 0.0797 % which means that on every $100 spent on assets, it made $0.0797 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2049 %, implying that it generated $0.2049 on every 100 dollars invested. Telix Pharmaceuticals' management efficiency ratios could be used to measure how well Telix Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.02 in 2024. Return On Capital Employed is likely to rise to 0.07 in 2024. At this time, Telix Pharmaceuticals' Other Current Assets are fairly stable compared to the past year. Return On Tangible Assets is likely to rise to 0.02 in 2024, whereas Total Assets are likely to drop slightly above 253.4 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Cheryl Madsen | Viracta Therapeutics | N/A | |
| Michael Morneau | Viking Therapeutics | 59 | |
| Clement Monteil | Virax Biolabs Group | N/A | |
| Helen Milton | Viridian Therapeutics | N/A | |
| Shan Wu | Viridian Therapeutics | N/A | |
| Dr MBA | Verrica Pharmaceuticals | 48 | |
| Joel Yeung | Virax Biolabs Group | N/A | |
| Stewart Brown | Viracta Therapeutics | N/A | |
| Michael Faerm | Viracta Therapeutics | 57 | |
| Lily Fu | Virax Biolabs Group | N/A | |
| Joakim Wijkstrom | Vanda Pharmaceuticals | 58 | |
| Ana Rodriguez | Dyadic International | N/A | |
| Anthony Casicano | Viridian Therapeutics | 47 | |
| Robert McRae | Viracta Therapeutics | N/A | |
| CPA CPA | Viking Therapeutics | 53 | |
| Christopher Hayes | Verrica Pharmaceuticals | 60 | |
| Joe Bonaccorso | Verrica Pharmaceuticals | 60 | |
| Biljana PharmD | Viracta Therapeutics | N/A | |
| MD MBA | Viridian Therapeutics | 59 | |
| Nigel MSc | Virax Biolabs Group | 59 | |
| Seth Harmon | Viridian Therapeutics | 44 | |
Management Performance
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0797 |
Telix Pharmaceuticals Leadership Team
Elected by the shareholders, the Telix Pharmaceuticals' board of directors comprises two types of representatives: Telix Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Telix. The board's role is to monitor Telix Pharmaceuticals' management team and ensure that shareholders' interests are well served. Telix Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Telix Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard MBA, Chief Therapeutics | ||
| BSc BSc, Chief Scientist | ||
| Lena LLB, Group Counsel | ||
| Andreas MD, Chief Advisor | ||
| Darren Patti, Group Officer | ||
| BEng DPhil, MD, CoFounder | ||
| Craig Ulrick, Chief Officer | ||
| Kyahn BA, Senior Relations | ||
| BBus FCPA, Group Officer | ||
| MBA MD, Group Officer |
Telix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Telix Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0797 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 5.33 B | ||||
| Shares Outstanding | 334.72 M | ||||
| Number Of Shares Shorted | 5.92 K | ||||
| Price To Book | 21.03 X | ||||
| Price To Sales | 8.55 X | ||||
| Revenue | 496.66 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.